Evidence map›Paper›PMID 40078946›Full record

ArticleBiosafety and health2024

Construction of a bivalent vaccine candidate against HAdV4/HAdV7 based on capsid-display strategy via Red-homologous recombination and counter-selection methodology.

Peng Wang, Yunting Shao, Xichun Yang, Wenning Zhang, Jianguang Zhou, Fang Huang, Shuang Liu, Jiping Zheng, Chengjun Wu, Shanhu Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosafety and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peng WangDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Yunting ShaoSchool of Basic Medical Sciences, Faculty of Medicine, Dalian University of Technology, Dalian 116024, China.
Xichun YangLab of Microbiological Engineering, School of Life and Health Sciences, Hainan University, Haikou 570228, China.
Wenning ZhangDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Jianguang ZhouDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Fang HuangDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Shuang LiuDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Jiping ZhengLab of Microbiological Engineering, School of Life and Health Sciences, Hainan University, Haikou 570228, China.
Chengjun WuSchool of Basic Medical Sciences, Faculty of Medicine, Dalian University of Technology, Dalian 116024, China.
Shanhu LiDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenoviruses (HAdVs) are major respiratory pathogens. Specifically, human adenovirus type 4 (HAdV4) and human adenovirus type 7 (HAdV7) are known for causing fever and pneumonia, with documented cases of fatalities among the population. In recent years, HAdV4/HAdV7 has been implicated in causing substantial outbreaks, leading to increased morbidity in multiple countries. Most HAdV4 and HAdV7 infections have been reported in North America, Asia, Europe, Africa, South America, Oceania, and the Middle East. Most fatalities occurred in North America (the United States) and Asia (China and Singapore). Engineered recombinant adenoviruses have played a crucial role as vaccine vectors. In this study, we constructed a recombinant adenovirus, Ad4ITRmut-Ad7E3, and evaluated it

Indexed as

Bivalent adenovirus vaccineCapsid-display strategyHexon epitope replacementITRs modification

Identifiers

PMID40078946
PMCPMC11895023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.